Search

Displaying results 881 - 890 of 1786 in total
  1. Drug

    Clodronic acid

    go.drugbank.com/drugs/DB00720
    ApprovedInvestigationalVet approved

    [A203111] Clodronic acid is not FDA approved, but is approved in Canada.[L13910]

  2. Drug

    Emtricitabine

    go.drugbank.com/drugs/DB00879
    ApprovedInvestigational

    [L9019] Emtricitabine was granted FDA approval on 2 July 2003.[L9019]

  3. Drug

    Metamfetamine

    go.drugbank.com/drugs/DB01577
    ApprovedIllicitInvestigationalWithdrawn

    The FDA withdrew its approval for the use of all parenteral drug products containing methamphetamine hydrochloride, a metamfetamine salt.[L43942]

  4. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.

  5. Drug

    Nylidrin

    go.drugbank.com/drugs/DB06152
    ApprovedWithdrawn

    Therefore, the FDA has withdrawn nylidrin from the U.S. market [L2286]. … FDA has considered nylidrin as "lacking substantial evidence of effectiveness" in cerebral ischemia, cerebral arteriosclerosis, and other cerebral circulatory insufficiencies.

  6. Drug

    Rucaparib

    go.drugbank.com/drugs/DB12332
    ApprovedInvestigational

    [A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 [A18745] and accelerated approval in December 2016. … On December 17, 2025, the FDA granted regular approval to rucaparib for adults with a deleterious BRCA mutation–associated metastatic castration-resistant prostate cancer (mCRPC) previously treated with

  7. Drug

    Berotralstat

    go.drugbank.com/drugs/DB15982
    ApprovedInvestigational

    [L41960] In December 2025, the FDA expanded Berotralstat pediatric use with approval of an oral pellet formulation for prophylaxis in children with HAE aged 2 and older.[L54793,L54798] … [A225106] Berotralstat was first approved by the FDA on December 3, 2020, as the first once-daily oral therapy to prevent angioedema attacks of HAE in adults and pediatric patients 12 years and older.

  8. Drug

    Mitapivat

    go.drugbank.com/drugs/DB16236
    ApprovedInvestigational

    [A245478] On January 5, 2026, the FDA also approved the use of in the treatment of anemia in adults with alpha- or beta-thalassemia, making it the first oral treatment for this condition.[L54953] … [A245478] On February 17, 2022, the FDA approved mitapivat as the first disease-modifying treatment for hemolytic anemia in adults with pyruvate kinase (PK) deficiency, a rare, inherited disorder leading

  9. Drug

    Oveporexton

    go.drugbank.com/drugs/DB21680
    Approved

    [L64069] The FDA approved oveporexton on August 5, 2026 for the treatment of narcolepsy type 1 (narcolepsy with cataplexy) in adults. … [L64068,L64069] It is the first orexin receptor agonist approved by the FDA and the first medicine to treat NT1 by targeting its underlying cause rather than individual symptoms.

  10. Drug

    Octasulfur

    go.drugbank.com/drugs/DB09353
    Approved

    Sulfur is a chemical element that is present in all living tissues. The most commonly used form of pharmaceutical sulfur is Octasulfur (S8). After calcium and phosphorus, it is the third most abundant mineral in the human body. Sulfur is...

    Mixtures: Prascion RA, Prascion RA Cream with Sunscreens